Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- S&P 500, Nasdaq hit record highs as Treasury yields stall, oil slips
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
| Beam Inc. (NASDAQ: BEAM) | Delayed: 25.25 -0.42 (1.64%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.67 | 52 Week High | $83.60 | |||
| Open | $26.80 | 52 Week Low | $82.96 | |||
| Day High | $26.94 | P/E | 11.27 | |||
| Day Low | $24.87 | EPS | $2.24 | |||
| Volume | 1,784,001 | |||||
| Beam Inc. (NASDAQ: BEAM) | Delayed: 25.25 -0.42 (1.64%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.67 | 52 Week High | $83.60 | |||
| Open | $26.80 | 52 Week Low | $82.96 | |||
| Day High | $26.94 | P/E | 11.27 | |||
| Day Low | $24.87 | EPS | $2.24 | |||
| Volume | 1,784,001 | |||||
